BBNX Beta Bionics, Inc.
$21.39▲ +4.29%
Healthcare
Other
After hours
$18.66▼ -12.76%
Oct 27, 6:00 PM ET
Volume 1.36M
Avg Volume (10D) 1.04M
Key Metrics & Fundamentals
Market Cap
$1.15B
P/E Ratio
–
Div Yield
0.00%
52W Range
8.80 - 32.71
% vs 50 MA
11.22%
% vs 200 MA
44.37%
RSI-14
65.2
MACD Histogram
+0.4000
Beta (1Y vs SPY)
1.24
Free Cash Flow
-$15.66M
Gross Rev
$32.01M
Gross Profit
$18.90M
EBITDA
-$24.46M
COGS
$13.11M
Operating Exp
$44.48M
Operating Income
-$25.58M
EBIT
-$25.58M
Pretax Income
-$23.40M
Net Income
-$23.40M
EPS (Diluted)
-0.53
Price & Volume History
Loading chart…
Recent News
Beta Bionics, Inc. (BBNX) Reports Q3 Loss, Beats Revenue Estimates
Zacks · Oct 27, 2026 4:15 PM ET
Beta Bionics Announces Third Quarter 2026 Financial Results and Updates Full Year 2026 Guidance
GlobeNewswire · Oct 27, 2026 4:02 PM ET
IQVIA Gears Up to Post Q3 Earnings: Here's What Investors Should Know
Zacks · Oct 22, 2026 8:58 AM ET
Beta Bionics, Inc. (BBNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zacks · Oct 20, 2026 9:00 AM ET
Jefferies & Co Initiates Coverage on Beta Bionics With Buy Rating, $30 Price Target
MT Newswires · Oct 12, 2026 7:23 AM ET
Barclays Says MedTech Stocks Are at Their Cheapest in a Decade — and Names 2 Stocks to Buy
TipRanks · Oct 11, 2026 2:00 PM ET
Beta Bionics (BBNX) Stock Fair Value Rises After Mint Clearance And Analyst Target Changes
Simply Wall St. · Oct 8, 2026 8:22 PM ET
Flutter upgraded, AppFolio downgraded: Wall Street's top analyst calls
The Fly · Oct 7, 2026 10:00 AM ET
Barclays Initiates Beta Bionics at Overweight With $30 Price Target
MT Newswires · Oct 7, 2026 8:07 AM ET
Beta Bionics Stock Down Despite iLet-Eversense 365 Integration Deal
Zacks · Sep 29, 2026 10:06 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See BBNX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.